Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and ...

EUROPEAN shares slipped on Friday, weighed down by disappointing earnings, concerns about the impact of US President-elect ...

Halozyme Therapeutics logged a -12.9% change during today's morning session, and is now trading at a price of $47.01 per ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...